Time to Treat First Acute Attack of Myelin Oligodendrocyte Glycoprotein Antibody-Associated DiseaseYoung Nam Kwon, Sung Min Kim, Kyong Jin Shin et al.|JAMA Neurology|2024Cited by 26
Early rituximab treatment reduces long-term disability in aquaporin-4 antibody-positive neuromyelitis optica spectrumSu Yeon Park, Young Nam Kwon, Sun‐Young Kim et al.|Journal of Neurology Neurosurgery & Psychiatry|2023Cited by 18
Comparison of MOG and AQP4 antibody seroprevalence in Korean adults with inflammatory demyelinating CNS diseasesJae‐Won Hyun, Ho Jin Kim, Hye Lim Lee et al.|Multiple Sclerosis Journal|2020Cited by 14
Evaluating Rituximab Failure Rates in Neuromyelitis Optica Spectrum Disorder: A Nationwide Real-World Study From South KoreaSu‐Hyun Kim, Ho Jin Kim, Ju‐Hong Min et al.|Journal of Clinical Neurology|2025Cited by 11
National Consensus Guidance for the Diagnosis and Management of Adult Patients with Myelin Oligodendrocyte Glycoprotein Antibody-Associated DiseaseYoung Nam Kwon, Ha Young Shin, Ki Hoon Kim et al.|Journal of Multiple Sclerosis and Neuroimmunology|2023Cited by 1